$390 Million is the total value of New Leaf Venture Partners, L.L.C.'s 19 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 5.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARVN | Sell | ARVINAS INC | $170,382,000 | +12.9% | 2,212,748 | -3.1% | 43.73% | +24.5% |
| CRNX | CRINETICS PHARMACEUTICALS INC | $44,282,000 | +1955.8% | 141,000 | 0.0% | 11.37% | +2168.7% | |
| EWTX | EDGEWISE THERAPEUTICS INC | $43,783,000 | -13.3% | 1,553,661 | 0.0% | 11.24% | -4.4% | |
| DCPH | DECIPHERA PHARMACEUTICALS INC | $33,140,000 | -38.9% | 1,209,571 | 0.0% | 8.51% | -32.6% | |
| OBSV | OBSEVA SA | $33,072,000 | +1029.9% | 900,501 | 0.0% | 8.49% | +1146.5% | |
| CMRX | CHIMERIX INC | $9,797,000 | -17.0% | 1,224,600 | 0.0% | 2.52% | -8.4% | |
| APTX | APTINYX INC | $9,311,000 | -5.7% | 3,290,079 | 0.0% | 2.39% | +4.0% | |
| PDSB | PDS BIOTECHNOLOGY CORP | $7,975,000 | +1396.2% | 117,242 | 0.0% | 2.05% | +1550.8% | |
| ALEC | ALECTOR INC | $7,073,000 | +3.4% | 339,569 | 0.0% | 1.82% | +14.0% | |
| ARAV | ARAVIVE INC | $5,660,000 | -9.3% | 946,423 | 0.0% | 1.45% | +0.1% | |
| CHMA | CHIASMA INC | $5,372,000 | +51.1% | 1,135,700 | 0.0% | 1.38% | +66.7% | |
| SRRA | SIERRA ONCOLOGY INC | $4,067,000 | -42.4% | 409,611 | 0.0% | 1.04% | -36.5% | |
| HARP | HARPOON THERAPEUTICS INC | $3,364,000 | -94.9% | 3,156,699 | 0.0% | 0.86% | -94.4% | |
| AVRO | AVROBIO INC | $2,805,000 | -29.9% | 315,550 | 0.0% | 0.72% | -22.7% | |
| ITRM | ITERUM THERAPEUTICS PLC | $2,729,000 | +32.9% | 1,456,303 | 0.0% | 0.70% | +46.4% | |
| COGT | COGENT BIOSCIENCES INC. | $2,658,000 | -39.6% | 501,530 | 0.0% | 0.68% | -33.5% | |
| XFOR | X4 PHARMACEUTICALS INC | $2,178,000 | -24.5% | 335,000 | 0.0% | 0.56% | -16.7% | |
| PASG | PASSAGE BIO | $1,471,000 | -96.6% | 2,497,922 | 0.0% | 0.38% | -96.3% | |
| ADXN | New | ADDEX THERAPEUTICS LTD | $478,000 | – | 50,000 | +100.0% | 0.12% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DECIPHERA THERAPEUTICS INC | 25 | Q3 2023 | 44.4% |
| CHIMERIX INC | 25 | Q1 2023 | 20.9% |
| SIERRA ONCOLOGY INC | 22 | Q2 2022 | 14.9% |
| ARVINAS INC | 21 | Q3 2023 | 44.8% |
| CRINETICS PHARMACEUTICALS INC | 21 | Q3 2023 | 11.4% |
| OBSEVA SA | 20 | Q4 2021 | 8.5% |
| AVROBIO INC | 20 | Q1 2023 | 1.7% |
| HARPOON THERAPEUTICS INC | 19 | Q3 2023 | 20.0% |
| ALECTOR INC | 19 | Q3 2023 | 4.6% |
| ITERUM THERAPEUTICS PLC | 18 | Q3 2022 | 3.8% |
View New Leaf Venture Partners, L.L.C.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-06 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-09 |
| 13F-HR | 2022-05-06 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
View New Leaf Venture Partners, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.